Dr. Tagliaferri is a proven executive recognized for advancing innovative therapies across immunology, oncology and other serious diseases –SAN ...
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...
SAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing ...
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology ...
ADARx Pharmaceuticals has dosed the first participant in its Phase III trial of ADX-324 for the prophylactic treatment of hereditary angioedema (HAE). ADX-324, an investigational short-interfering RNA ...
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback